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Abstract
Introduction: Health care-associated pneumonia (HCAP) has been proposed as a new category of respiratory
infection to identify patients at risk of multidrug-resistant (MDR) pathogens. The American Thoracic Society’s
recommendation for HCAP treatment is to use broad-spectrum and multiple antibiotics. However, this strategy
may be economically expensive and promote antimicrobial resistance when a multisensitive pathogen is not
identified.
Methods: We prospectively included all patients presenting with HCAP in the emergency department. Blood
cultures and fiberoptic bronchoscope-guided distal protected small volume bronchoalveolar lavage (FODP mini-
BAL) were performed in each patient. Empirical antibiotic therapy was adapted when microbiological findings were
available. The primary objective was to assess whether FODP mini-BAL is more efficient than blood cultures in
identifying pathogens with the ratio of identification between both techniques as principal criteria.
Results: We included 54 patients with HCAP. Pathogens were identified in 46.3% of cases using mini-BAL and in
11.1% of cases using blood cultures (P <0.01). When the patient did not receive antibiotic therapy before the
procedure, pathogens were identified in 72.6% of cases using mini-BAL and in 9.5% of cases using blood cultures
(P <0.01). We noted multidrug-resistant pathogens in 16% of cases. All bronchoscopic procedures could be
performed in patients without complications.
Conclusions: FODP mini-BAL was more efficient than blood cultures for identifying pathogens in patients
presenting with HCAP. When bacteriological identification was obtained, antibiotic therapy was adapted in 100% of
cases.
Introduction
Health care-associated pneumonia (HCAP) is associated
with higher mortality than community-acquired pneumo-
nia, because patients presenting with HCAP are at risk of
multidrug-resistant (MDR) pathogens and seem to receive
initially inappropriate therapy [1]. Indeed, empirical anti-
biotic therapy recommended for the management of com-
munity-acquired pneumonia is not adapted [2,3]. That is
why guidelines recommend the use of broad-spectrum and
multiple antibiotics in patients presenting with HCAP [4].
However, some recent studies focus on the fact that
HCAP does not correlate well with the presence of resis-
tant pathogens and that can lead to unnecessary antibiotic
prescription with economic and ecological consequences
[5]. That is why accurate microbiological identification is
essential in the management of HCAP to de-escalate anti-
biotic therapy [6]. Actually, bacteriological diagnosis in
pneumonia is based on blood cultures. Sputum culture
may be sensitive for the diagnosis of pathogens but it is no
longer performed for the diagnosis of pneumonia (except
tuberculosis) in our hospital because of its lack of specifi-
city. However, the identification rate using blood cultures
remains low, up to 3.4% in an emergency department [7].
Mini-bronchoalveolar lavage (BAL) has been shown to be
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a useful tool in identifying pathogens, as in ventilator-asso-
ciated pneumonia, with identification in up to 46.2% of
cases, or in acute hypoxemic respiratory failure requiring
noninvasive ventilation [8,9].
We conducted a prospective study to assess whether
fiberoptic bronchoscope-guided distal-protected small
volume bronchoalveolar lavage (FODP mini-BAL) with
quantitative cultures was more efficient than blood cul-
tures to identify pathogens in patients presenting with
HCAP with the ratio of identification between the techni-
ques as principal criteria.
Material and methods
Study design
The study was a prospective cohort and was approved by
the local hospital’s ethics committee. Patients admitted
between February 2008 and February 2010 to the emer-
gency department of Sainte Anne Military Teaching Hos-
pital, Toulon, France, were eligible for enrollment into the
study. Informed consent was obtained from each patient.
Patients
We included all patients in the emergency department
who were diagnosed with HCAP. Pneumonia was defined
as the presence of a new infiltrate on a chest radiograph
plus one or more of the following: fever (temperature
>38.0°C) or hypothermia (temperature <35.0°C); new
cough with or without sputum production; pleuritic chest
pain; dyspnea; and altered breath sounds on auscultation
[6]. HCAP was defined by pneumonia and one or more of
the four criteria defined by the American Thoracic Society
(ATS) [2]: hospitalized for two or more days in an acute
care facility within 90 days before infection; resident of a
nursing home or long-term care facility; attending a hospi-
tal or hemodialysis clinic, or received recent intravenous
antimicrobial therapy, immunosuppressive therapy, or
wound care within 30 days of infection. The exclusion cri-
teria were: age younger than 18 years; use of antiplatelet
drugs; use of anti-vitamin K medications; coagulation fail-
ure; opposition from the patient; judiciary protection of
the patient; and bronchospasm.
Diagnostic procedure
The diagnostic procedure was performed after initial
symptomatic treatment. Evaluation of level of care and
respiratory support needed by the patient was made by
the intensivist on clinical grounds and according to pub-
lished guidelines. Microbiological diagnosis was made as
soon as possible, using FODP mini-BAL and blood cul-
tures for each patient performed at the same time. Posi-
tive pathogen identification with mini-BAL was defined
as >103CFU/mL [8,10].
All patients were on non-invasive ventilation (NIV)
(BiPAP Vision®, Philips Respitronics, Amsterdam,
Netherlands) throughout the FODP mini-BAL, except
for those who required endotracheal intubation prior to
the procedure (Figure 1). The procedure was performed
in the emergency department when the patient did not
initially require tracheal intubation. The fiberoptic
bronchoscope was positioned in the lobar bronchia
where the pneumonia was localized on chest x-ray. The
telescopic catheter (Combicath®, Prodimed division
Plastimed, Le Plessis-Bouchard, FRANCE) was passed
through the bronchoscope operator channel. The inter-
nal catheter was placed in the distal position and 20 mL
of normal saline was infused, then secretions were
removed with a syringe [10-12]. Two series of aerobic
and anaerobic blood cultures were conducted at the
same time. Blood samples were immediately taken to
the laboratory.
Antibiotic therapy
Broad-spectrum antibiotic combination with piperacillin-
tazobactam, ciprofloxacin, and vancomycin was started
as soon as possible according to ATS recommendations
[4]. Treatment was adapted when microbiological results
were available. When no pathogen was identified, initial
treatment was prolonged to 14 days [2].
De-escalation is defined by adaptation from a broad-
spectrum antibiotics combination therapy to a targeted
and shortened treatment guided by antibiogram. When
identification and antibiogram were available, the duration
of treatment was adapted to the identified bacteria: 7 days
in all cases except for Pseudomonas aeruginosa (14 days),
Legionnella pneumophilia (21 days) and Mycobacterium
tuberculosis (6 months).
Data recorded
We recorded the patients’ characteristics, including sex
ratio, Fine score, and HCAP criteria (Table 1). We used
the Fine score to categorize the severity of pneumonia
[13,14].
Complications possibly related to bronchoscopy were
categorized as follows: death in the first six hours; requir-
ing tracheal intubation in the first six hours; requiring
more than six hours of continuous NIV after mini-BAL
without requiring NIV before mini-BAL; hemoptysis; and
pneumothorax.
Statistical analysis
The primary endpoint was to compare the pathogen
identification rate of two microbiological techniques:
blood cultures versus FODP mini-BAL. Deschamps et al.
reported a 40% identification rate with BAL and 5.7%
with blood cultures in patients with hospital-acquired
pneumonia [15]. According to these previous results, we
calculated that 49 patients were required in order to have
an 80% power for detecting a 25% absolute difference in
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pathogen identification between the fiberoptic and blood
culture techniques with a two-sided chi-square test and
a set at 0.05. Continuous variables were compared using
paired or unpaired Wilcoxon rank-sum tests. Categorical
variables were compared using the chi-square test or
Fisher’s exact test when appropriate. A P-value < .05 was
considered statistically significant. All statistical analyses
were performed using JMP 8.0.1 statistical software (SAS
Institute, Cary, NC, USA).
Results
Patient characteristics
Between February 2008 and February 2010, 49,706
patients were admitted to the emergency department; 542
patients had pneumonia and 75 patients met HCAP cri-
teria. We excluded 21 patients: 13 for exclusion criteria, 5
for technical problems (unavailable fiberscope or operator)
and 3 for missing data. Finally, 54 patients with HCAP
were included in the study (Figure 2). Patient characteris-
tics are shown in Table 1. A total of 27 patients were hos-
pitalized in the ICU (50%), 9 in the intermediate care
department (17%), 11 in the respiratory department (20%)
and 7 in other departments (13%) (Figure 2). The mean
Fine score was 134 ± 17.5 without antibiotic therapy ver-
sus 156 ± 19.5 with previous antibiotic therapy (P <0.05).
The mean CURB65 score was 1.6 ± 1.
Among the patients, 33 had received antibiotic therapy
and 21 did not receive antibiotic therapy before the patho-
gen identification procedures.
Diagnostic procedure
All 54 patients had blood cultures and fiberoptic broncho-
scopy-guided mini-BAL. We completed 37 mini-BAL pro-
cedures in patients with NIV support and 17 in intubated
Figure 1 Fiberoptic bronchoscope-guided distal protected small volume bronchoalveolar lavage (FODP mini-BAL). 1) FODP mini-BAL
during non invasive ventilation. 2) Specific interface to perform fiberoptic bronchoscopy during non invasive ventilation. 3) Telescopic catheter
Combicath® before deployment. 4) Telescopic catheter Combicath® deployed.
Lacroix et al. Critical Care 2013, 17:R24
http://ccforum.com/content/17/1/R24
Page 3 of 8
patients with mechanical ventilation support. No compli-
cations possibly related to bronchoscopy were reported.
Microbiological identification rate
Among the 54 patients, pathogens were identified in 25
patients (46.3%) using mini-BAL, and in 6 patients
(11.1%) using blood cultures (P < .01) (Figure 3). When
both blood cultures and mini-BAL were positive, they
always identify the same organism. Bacteriological identi-
fication revealed a broad spectrum of bacteria (Table 2).
Among 28 identified pathogens, 23 wild-type resistance
phenotype or had low levels of drug resistance and 5
were MDR.
Twenty-one patients had not received previous anti-
biotic therapy. Among these patients, we obtained bac-
teriological diagnoses for 16 patients (76.2%) using
FODP mini-BAL and for 2 patients (9.5%) using blood
cultures (Figure 3). Thirty-three patients had received
previous antibiotic therapy before the microbiological
diagnostic procedure. We obtained identification for 9
patients (27.3%) using mini-BAL and for 4 patients
(12.1%) using blood cultures (Figure 3). The relative risk
of non-identification with previous antibiotic therapy
versus without previous antibiotic therapy with FODP
mini-BAL is 3.3 (95% confidence interval, 1.5 to 7.25).
In the patients with bacteriological identification, we
studied the effectiveness of the initial antibiotic therapy.
With the broad-spectrum treatment of the study, three
initial treatments were ineffective on the pathogen (M.
tuberculosis, Escherichia coli BLSE, and L. pneumophila).
In theory, if we used antibiotic treatment of severe
community acquired pneumonia, with combined Cef-
triaxon/Levofloxacin, six initial treatments were ineffec-
tive (three P. aeruginosa, M. tuberculosis, E. coli BLSE,
and L. pneumophila) and treatments were not optimum
for three patients infected by Staphylococcus aureus.
De-escalation rate
When bacteriological identification was obtained, initial
antibiotic therapy could be adapted to the antibiogram
in 100% of cases.
Discussion
To our knowledge, this is the first study to focus on bac-
teriological diagnosis using FODP mini-BAL in HCAP
patients admitted to an emergency department. The main
result is that this technique is a more effective method to
obtain pathogen identification than blood culture (46.3%
versus 11.1% P < .01). This result is concordant with pre-
vious studies. Deschamps et al. observed a similar identifi-
cation rate in the context of hospital-acquired pneumonia
with BAL and blood cultures [15]. Pathogen identification
is more successful when FODP mini-BAL is performed
before antibiotic therapy (76.2% versus 27.3%; P < .001;
relative risk of non-identification was 3.3 (95% confidence
interval, 1.5 to 7.25). This result suggests that if decided,
Table 1 Patients’ characteristics
Total
Number 54




























Non-invasive ventilation 37 (68%)
Tracheal intubation 17 (32%)
Comorbidities
Neoplasic disease 19 (35.2%)
Liver disease 3 (5.6%)
Congestive heart failure 12 (22.2%)
Cerebrovascular disease 4 (7.4%)
Renal disease 13 (24.1%)
Physical examination findings
Altered mental status 17 (31.5%)
Respiratory rate >30 breaths/min 31 (57.4%)
Systolic blood pressure <90 mmHg 11 (20.4%)
Pulse >125 beats/min 28 (51.9%)
Laboratory and radiographic findings
Arterial pH <7.35 16 (29.6%)
Blood urea nitrogen ≥30 mg/dL 29 (53.7%)
Sodium <130 mmol/L 10 (18.5%)
Glucose ≥250 mg/dL (14 mmol/L) 6 (11.1%)
Hematocrit <30% 5 (9.3%)
Partial pressure of arterial oxygen <60 mmHg 35 (64.8%)
Pleural effusion 12 (22.2%)
HCAP Criteria:
Resident of a nursing home or long-term care facility 6 (11.1%)
Hospitalized for two or more days in an acute care
facility within 90 days of infection
14 (26%)
Attended a hospital or hemodialysis clinic or received
recent intravenous antimicrobial therapy,
immunosuppressive therapy, or wound care within 30
days of infection
33 (61%)
Nursing, intravenous infusion, or wound care at home
within 30 days of infection
16 (29.6%)
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this exam should be completed promptly and before the
beginning of antibiotic treatment.
We identified 28 bacteria, 5 of which were MDR. A sec-
ondary goal of this study was to evaluate the pertinence of
the HCAP categorization in our hospital. We evaluated the
empirical antibiotic therapy comparated to antibiogram.
If we use severe community acquired pneumonia antibiotic
therapy (cefriaxone combined with levofloxacin), 6/28
(21.5%) treatments will be inefficient (3 P. aeruginosa,
M. tuberculosis, E. coli BLSE, and L. pneumophila). This
result justifies HCAP categorization and the ATS strategy















































Figure 2 Flow chart. (a) HCAP criteria: Hospitalized for two or more days in an acute care facility within 90 days of infection; resident of a
nursing home or long-term care facility; attended a hospital or hemodialysis clinic, or received recent intravenous antimicrobial therapy,
immunosuppressive therapy, or wound care within 30 days of infection. (b) Exclusion criteria: Younger than 18 years; patient refusal; coagulation
disorders; judiciary protected patient; bronschospasm.
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Falcone et al. study indicates that a broad-spectrum
empirical approach may be associated with improved out-
come and reduction in the length of hospitalization [16].
However, 23 (82%) of the bacterial strains identified had
wild-type resistance phenotype or had low-level resistance
and 3 (10%) were resistant to our broad-spectrum antibio-
tics therapy. This result favors the use of an efficient
pathogen identification technique to adapt antibiotic ther-
apy with two goals: avoid the economic and ecological cost
of an unnecessary antibiotics prescription and be efficient
against bacteria resistant to the initial antibiotic therapy.
This is why we propose to use early FODP mini-BAL in
the emergency department. However, the worse efficien-
cies of mini-BAL after antibiotic therapy and the logistics
required favor performing mini-BAL only for patients
without previous antibiotic therapy.
We have to recognize that our local bacterial ecology is
quite different from that described in other areas, as in the
study by Kollef et al. who reported a higher proportion of
S. aureus and methicillin-resistant S. aureus in a multi-
institutional database of US acute-care hospitals [3].
Our study shows that fiberoptic bronchoschope-guided
mini-BAL is a feasible procedure in patients with HCAP.
We experienced no major complications despite the pro-
portion of patients who were more than 80 years old
(26%). Some studies have already reported the feasibility
and the safety of this technique in a different context.
Azoulay et al. used fiberoptic BAL (50 mL serum saline)
in patients with hypoxemic acute respiratory failure. As in
our study, they concluded that this strategy was safe, with
no increased risk of endotracheal intubation [17]. In the
literature, this procedure is often described under NIV
when patients are not intubated. Maitre et al. used contin-
uous positive airway pressure (CPAP) during fiberoptic
bronchoscopy in hypoxemic patients to prevent subse-
quent respiratory failure [18]. Da Conceiçao et al. per-
formed BAL in hypoxemic and hypercapnic chronic
obstructive pulmonary disease patients using bilevel venti-
latory support [19].
The use of bronchoscopy allows us to select the sampling
site with chest X-ray. The low volume used for mini-BAL
(20 ml) probably has a better tolerance than the larger
volume used for BAL (250 ml).
Based on our results, we agree with Brito et al. when
they suggest that HCAP is a heterogeneous disease and
that all patients do not need the same broad-spectrum
antibiotic therapy [20]. Our bacteriological results are in
agreement with this idea. Moreover, a recent study sug-
gested that the HCAP concept does not correlate well with
the presence of infection due to a resistant pathogen [5].
From our point of view, this debate promotes the use of an
efficient pathogen identification technique to avoid the use
of broad-spectrum antibiotics and to de-escalate initial
antibiotics as soon as possible [21]. Besides, some authors
propose to redefine the concept of HCAP which may con-
tribute to confusion more than provide a guide to pneumo-
nia management, and potentially leads to overtreatment
[22]. Achieving bacteriological identification in a larger
Figure 3 Bacteriological identification blood cultures versus fiberoptic bronchoscope-guided distal protected small volume
bronchoalveolar lavage (FODP mini-BAL). *P <0.05
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population study should define new HCAP criteria and
adapt empirical antibiotic therapy to these new categories.
Our study has several limitations. It appears that the
main limitation of our strategy is the availability of the
fiberoptic bronchoscope and an experienced operator
when the patient is admitted to the emergency department.
Indeed, the examination should be completed promptly
after hospital admittance so that antibiotic therapy can be
started as soon as possible. We describe our local bacterio-
logical ecology. It has been shown that pathogens and their
drug-sensitivity may be different in other areas [3]. An
additional limitation is that our study is observational. We
did not compare the effectiveness of our strategy regarding
outcomes with an antibiotic strategy based on non-invasive
pathogen identification. Large scale, multi-center studies
are needed to confirm our strategy regarding outcome, as
well as ecological and economic costs.
Conclusions
Our study demonstrates that early FODP mini-BAL is safe
and more efficient than blood cultures to identify patho-
gens and de-escalate antibiotic therapy in patients present-
ing with HCAP. We demonstrated that HCAP
classification is relevant in our hospital. However, other
studies are needed to compare the efficiency of this strategy
including mini-BAL with a non-invasive strategy including
sputum cultures, blood cultures, and an epidemiologic
approach in terms of outcome and the economic impact of
early antibiotic de-escalation.
Key messages
• Early FODP mini-BAL is safe and more efficient
than blood cultures to identify pathogens and de-
escalate antibiotic therapy in the treatment of HCAP
(46.3% versus 11.1%, P < .01).
• FODP mini-BAL should preferentially be com-
pleted promptly and before the beginning of treat-
ment (relative risk of non-identification was 3.3 (95%
confidence interval, 1.5 to 7.25).
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Table 2 Bacteriological identification with FODP mini-BAL
Pathogens Number of patients
Without previous antibiotic therapy Previous antibiotic therapy Total
Pathogens per sample
1 14 8 22
2 2 1 3
Gram positive pathogens










Haemophilus influenza 1 2 3





Enterobacter aerogenes 1 0 1
Enterobacter cloacae 1 0 1
Serratia marcescens 0 1 1
Proteus vulgaris 0 1 1
Other pathogens
Legionella pneumophila 0 1 1
Mycobacterium tuberculosis 1 0 1
FODP mini-BAL; fiberoptic bronchoscope-guided distal protected small volume bronchoalveolar lavage
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